Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.50 |
| ▸ | APP | P05067 | 3/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 2/20 | 0.46 |
| ▸ | NOS1 | P29475 | 2/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL55548 | 0.97 | — | — | |
| Ammonia Solution, Strong SCHEMBL28921856 | 0.94 | APP (0.55) | APPCA2CYP2A6CA12CA9 | |
| Nitrogen SCHEMBL28836575 | 0.94 | APP (0.55) | APPCA2CYP2A6CA12CA9 | |
| Acetonitrile SCHEMBL9172655 | 0.92 | CYP2A6 (0.55) | APPCA2CYP2A6CA12CA9 | |
| SCHEMBL1006683 | 0.89 | MMP3 (0.58) | APPCA2CYP2A6CA12CA9 | |
| Bicarbonate SCHEMBL22529849 | 0.85 | CA2 (0.50) | APPCA2CA12CA9LOXL2 | |
| SCHEMBL212777 | 0.83 | ALDH1A1 (0.54) | APPCA2CYP2A6CA12CA9 | |
| SCHEMBL211692 | 0.83 | ALDH1A1 (0.54) | APPCA2CYP2A6CA12CA9 | |
| SCHEMBL22044381 | 0.83 | CYP19A1 (0.57) | APPCA2CYP2A6CA12CA9 | |
| SCHEMBL7899597 | 0.83 | CYP19A1 (0.54) | APPLOXL2ALDH1A1PGRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108752237-A | A kind of new preparation process of p-amino-benzamidine hydrochloride | 四川青木制药有限公司 | 2018-11-06 | — | — | CN | claimed |
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | claimed |
| EP-2367822-A1 | TRICYCLIC AZAINDOLES | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | claimed |
| WO-2010080253-A1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | claimed |
| CN-114560787-B | Preparation method of dabigatran etexilate intermediate p-aminobenzonitrile | 内蒙古京科医药科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-114560787-A | Preparation method of dabigatran etexilate intermediate p-aminobenzonitrile | 内蒙古京科医药科技有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-108752237-A | A kind of new preparation process of p-amino-benzamidine hydrochloride | 四川青木制药有限公司 | 2018-11-06 | — | — | CN | disclosed |
| US-8796316-B2 | Azole compounds used as tuberculostatic and leishmanicide agents | Fundacão Oswaldo Cruz—FIOCRUZ (BR) | 2014-08-05 | — | — | US | disclosed |
| US-20130274298-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ (BR) | 2013-10-17 | — | — | US | disclosed |
| US-8436027-B2 | Azole compounds used as tuberculostatic and leishmanicide agents | Fundacão Oswaldo Cruz—FIOCRUZ (BR) | 2013-05-07 | — | — | US | disclosed |
| US-20110269803-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ - FIOCRUZ (BR) | 2011-11-03 | — | — | US | disclosed |
| EP-2367822-A1 | TRICYCLIC AZAINDOLES | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| WO-2007019660-A2 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | Fundação Oswaldo Cruz - FIOCRUZ (BR) | 2007-02-22 | — | — | WO | disclosed |
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | FURET PASCAL | 2006-05-18 | — | — | US | disclosed |
| EP-1521749-A1 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | Novartis AG (CH) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005282-A1 | PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | disclosed |
| US-6492541-B2 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, novel intermediates and their use | DEGUSSA-HULS AKTIENGESELLSCHAFT (DE) | 2002-12-10 | — | — | US | disclosed |
| US-20020045763-A1 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, novel intermediates and their use | DEGUSSA-HULS AKTIENGENSELLSCHAFT | 2002-04-18 | — | — | US | disclosed |
| US-20010025109-A1 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, novel intermediates and their use | DEGUSSA-HULS AKTIENGENSELLSCHAFT | 2001-09-27 | — | — | US | disclosed |
| US-6281364-B1 | CYCLIZATION | DEGUSSA-HULS AG (DE) | 2001-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274298-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | CYP51A1, IPO5, TBC1D5 | CA2 984/4885APP 4515/4885CYP2A6 755/4885 |
| US-20110269803-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | CBR3, NOX3, NR2C2 | CA2 2416/4885APP 4833/4885CYP2A6 198/4885 |
| US-20010025109-A1 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, novel intermediates and their use | AAAS, IL4I1, PGLS | CA2 2556/4885APP 1456/4885CYP2A6 446/4885 |
| US-20020045763-A1 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, novel intermediates and their use | AAAS, IL4I1, PGLS | CA2 2556/4885APP 1456/4885CYP2A6 446/4885 |
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | MKI67, CCNI, PAH | CA2 3712/4885APP 1176/4885CYP2A6 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.